Cancer
Malignant Lung Neoplasm
CI-CAN-00001140Explore in graph →
Top-level2,648 active trials51 approved drugs619 evidence items
- NCIt
- C7377
- ICD-10
- C33-C34
- DOID
- 1324
- Other
- 1 more code
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00001140Explore in graph →
Clinical trials
11,122 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,489)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00030771 | Preoperative Chemoradiotherapy vs. Chemotherapy Alone in NSCLC Patients | completed | Phase 3 | 232 | Swiss Cancer InstituteOTHER | 3 | Jan 17, 2024 | clinicaltrials |
| NCT01459497 | Hypofractionated Image-Guided Radiation Therapy (IGRT) in Patients With Stage II-III Non-Small Cell Lung Cancer | completed | Phase 3 | 103 | University of Texas Southwestern Medical CenterOTHER | 1 | Jan 17, 2024 | clinicaltrials |
| NCT01763645 | A Safety and Efficacy Study of BCD-021 With Paclitaxel and Carboplatin Compared to Avastin With Paclitaxel and Carboplatin in Non-Small Cell Lung Cancer | completed | Phase 3 | 353 | BiocadINDUSTRY | 4 | Jan 11, 2024 | clinicaltrials |
| NCT05318443 | A Study Exploring Efficacy of SIBP04 in Subjects With Non-squamous Non-small Cell Lung Cancer | completed | Phase 3 | 512 | Shanghai Institute Of Biological ProductsINDUSTRY | 1 | Dec 27, 2023 | clinicaltrials |
| NCT03802240 | Sintilimab ± IBI305 Plus Chemotherapy (Pemetrexed + Cisplatin) for EGFRm + Locally Advanced or Metastasis Non-Squamous NSCLC Patients After EGFR-TKI Treatment Failure | completed | Phase 3 | 492 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Nov 27, 2023 | clinicaltrials |
| NCT01774721 | ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC. | completed | Phase 3 | 452 | PfizerINDUSTRY | 7 | Nov 14, 2023 | clinicaltrials |
| NCT02125461 | A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer(PACIFIC) | completed | Phase 3 | 713 | AstraZenecaINDUSTRY | 26 | Oct 10, 2023 | clinicaltrials |
| NCT02864251 | A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy(CheckMate722) | completed | Phase 3 | 367 | Bristol-Myers SquibbINDUSTRY | 10 | Sep 28, 2023 | clinicaltrials |
| NCT03302234 | Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-Small Cell Lung Cancer (NSCLC) (MK-3475-598/KEYNOTE-598) | completed | Phase 3 | 568 | Merck Sharp & Dohme LLCINDUSTRY | 24 | Sep 26, 2023 | clinicaltrials |
| NCT00795340 | Cediranib, Paclitaxel, and Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer | completed | Phase 3 | 306 | NCIC Clinical Trials GroupNETWORK | 2 | Aug 22, 2023 | clinicaltrials |
| NCT01000025 | PF-00299804 in Stage IIIB or Stage IV Non-Small Cell Lung Cancer Not Responding to Standard Therapy for Advanced or Metastatic Cancer | completed | Phase 3 | 720 | NCIC Clinical Trials GroupNETWORK | 12 | Aug 22, 2023 | clinicaltrials |
| NCT00245154 | Paclitaxel + Carboplatin With/Out Cediranib Maleate in Stage III or Stage IV Non-Small Cell Lung Cancer | completed | Phase 2 / Phase 3 | 296 | NCIC Clinical Trials GroupNETWORK | 6 | Aug 4, 2023 | clinicaltrials |
| NCT02763579 | A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)(IMpower133) | completed | Phase 3 | 503 | Hoffmann-La RocheINDUSTRY | 21 | Jul 28, 2023 | clinicaltrials |
| NCT02481830 | Effectiveness Study of Nivolumab Compared to Chemotherapy in Patients With Relapsed Small-cell Lung Cancer(CheckMate331) | completed | Phase 3 | 569 | Bristol-Myers SquibbINDUSTRY | 25 | Jul 27, 2023 | clinicaltrials |
| NCT01107626 | Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer | completed | Phase 3 | 1,516 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Jul 7, 2023 | clinicaltrials |
| NCT00008385 | Selenium in Preventing Tumor Growth in Patients With Previously Resected Stage I Non-small Cell Lung Cancer | completed | Phase 3 | 1,772 | ECOG-ACRIN Cancer Research GroupNETWORK | 2 | Jul 5, 2023 | clinicaltrials |
| NCT03689634 | Move For Surgery - A Novel Preconditioning Program(MFS) | completed | Phase 3 | 102 | St. Joseph's Healthcare HamiltonOTHER | 1 | Jul 3, 2023 | clinicaltrials |
| NCT00003235 | Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Can Not Be Surgically Removed | completed | Phase 3 | 294 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jun 15, 2023 | clinicaltrials |
| NCT03728556 | A Study of CS1001 in Subjects With Stage III Non-Small Cell Lung Cancer | completed | Phase 3 | 381 | CStone PharmaceuticalsINDUSTRY | 1 | Jun 15, 2023 | clinicaltrials |
| NCT02766335 | Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers | completed | Phase 2 / Phase 3 | 116 | SWOG Cancer Research NetworkNETWORK | 1 | May 25, 2023 | clinicaltrials |
| NCT01257139 | Trial Involving Subjects Over 70 Years of Age With Non Small-cell Lung Cancer of Stage IV and Comparing a "Classical" Strategy of Treatment Allocation, With an"Optimized" Strategy Allocating the Same Treatments(ESOGIA) | completed | Phase 3 | 490 | Rennes University HospitalOTHER | 1 | Apr 3, 2023 | clinicaltrials |
| NCT00385606 | Study of Rofecoxib and Prolonged Constant Infusion of Gemcitabine in the Polychemotherapy Treatment of Advanced NSCLC | completed | Phase 2 / Phase 3 | 400 | National Cancer Institute, NaplesOTHER | 1 | Mar 23, 2023 | clinicaltrials |
| NCT04241315 | ELUCIDATE: Enabling Lung Cancer Identification Using Folate Receptor Targeting(Elucidate) | completed | Phase 3 | 112 | On Target Laboratories, LLCINDUSTRY | 1 | Mar 23, 2023 | clinicaltrials |
| NCT01763671 | Paclitaxel-bevacizumab in Advanced Lung Cancer(Ultimate) | completed | Phase 3 | 166 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Mar 14, 2023 | clinicaltrials |
| NCT01850303 | Maintenance After Induction Chemotherapy in Elderly Patients With Advanced Non-small Cell Lung Cancer(MODEL) | completed | Phase 3 | 632 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Mar 14, 2023 | clinicaltrials |
| NCT02041533 | An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026) | completed | Phase 3 | 541 | Bristol-Myers SquibbINDUSTRY | 26 | Mar 2, 2023 | clinicaltrials |
| NCT03351361 | Nivolumab and Ipilimumab Versus Chimiotherapy in First Line Treatment in PS 2 or Elderly in Advanced NSCLC Patients(eNERGY) | completed | Phase 3 | 217 | Rennes University HospitalOTHER | 1 | Mar 1, 2023 | clinicaltrials |
| NCT03150875 | A Study Comparing the Efficacy and Safety Between IBI308 and Docetaxel in Patients With Advanced or Metastatic NSCLC | completed | Phase 3 | 290 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Feb 28, 2023 | clinicaltrials |
| NCT02713867 | A Dose Frequency Optimization,Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer Who Received Up to 12 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks(CheckMate 384) | completed | Phase 3 | 363 | Bristol-Myers SquibbINDUSTRY | 8 | Feb 14, 2023 | clinicaltrials |
| NCT03856411 | A Study to Evaluate the Efficacy and Safety of Toripalimab or Placebo Combined With Chemotherapy in Treatment-naive Advanced NSCLC | completed | Phase 3 | 465 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Feb 1, 2023 | clinicaltrials |
| NCT03196986 | mil60 Versus Bevacizumab in Patients With Treatment-naïve Non-squamous Non-small Cell Lung Cancer | completed | Phase 3 | 517 | Beijing Mabworks Biotech Co., Ltd.INDUSTRY | 1 | Jan 31, 2023 | clinicaltrials |
| NCT03682224 | Exparel and Marcaine for Pain Management in Thoracoscopic Lobectomy Patients(BEMP) | completed | Phase 3 | 57 | Southern Illinois UniversityOTHER | 1 | Jan 12, 2023 | clinicaltrials |
| NCT02813785 | A Study of Atezolizumab Compared With Docetaxel in Non-Small Cell Lung Cancer (NSCLC) After Failure With Platinum-Containing Chemotherapy(IMpower210) | completed | Phase 3 | 565 | Hoffmann-La RocheINDUSTRY | 5 | Jan 10, 2023 | clinicaltrials |
| NCT02538666 | An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based Chemotherapy(CheckMate 451) | completed | Phase 3 | 907 | Bristol-Myers SquibbINDUSTRY | 32 | Jan 5, 2023 | clinicaltrials |
| NCT00017407 | Carboplatin and Paclitaxel With or Without ISIS 3521 in Treating Patients With Non-Small Cell Lung Cancer | completed | Phase 3 | — | Ionis Pharmaceuticals, Inc.INDUSTRY | 1 | Dec 5, 2022 | clinicaltrials |
| NCT02066636 | A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen(CheckMate153) | completed | Phase 3 | 1,428 | Bristol-Myers SquibbINDUSTRY | 2 | Oct 27, 2022 | clinicaltrials |
| NCT03066778 | A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604) | completed | Phase 3 | 453 | Merck Sharp & Dohme LLCINDUSTRY | 19 | Oct 3, 2022 | clinicaltrials |
| NCT01968941 | Stereotactic Body Radiotherapy Versus Conventional Radiotherapy in Medically-Inoperable Non-Small Lung Cancer Patients(LUSTRE) | completed | Phase 3 | 324 | Ontario Clinical Oncology Group (OCOG)OTHER | 1 | Sep 21, 2022 | clinicaltrials |
| NCT00377156 | Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases | completed | Phase 3 | 213 | Alliance for Clinical Trials in OncologyOTHER | 2 | Sep 16, 2022 | clinicaltrials |
| NCT03922997 | A Study to Investigate the Safety and Efficacy of Atezolizumab in Previously-Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | completed | Phase 3 | 101 | Hoffmann-La RocheINDUSTRY | 1 | Sep 9, 2022 | clinicaltrials |
| NCT04342377 | The Canada Lymph Node Score Project: A Crossover Trial(CLNS) | completed | Phase 3 | 80 | St. Joseph's Healthcare HamiltonOTHER | 1 | Jul 27, 2022 | clinicaltrials |
| NCT00347412 | Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer | completed | Phase 3 | 903 | Cellectar Biosciences, Inc.INDUSTRY | 12 | Jul 25, 2022 | clinicaltrials |
| NCT00966914 | Phase 3 Study of Tavocept Versus Placebo in Patients With Newly Diagnosed or Relapsed Advanced Primary Adenocarcinoma of the Lung Treated With Docetaxel or Paclitaxel Plus Cisplatin | completed | Phase 3 | 540 | BioNumerik Pharmaceuticals, Inc.INDUSTRY | 6 | Jul 13, 2022 | clinicaltrials |
| NCT00533949 | High-Dose or Standard-Dose Radiation Therapy and Chemotherapy With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery | completed | Phase 3 | 544 | Radiation Therapy Oncology GroupNETWORK | 2 | Jun 21, 2022 | clinicaltrials |
| NCT00913705 | Neoadjuvant or Adjuvant Chemotherapy in Patients With Operable Non-small-cell Lung Cancer(NATCH) | completed | Phase 3 | 624 | Spanish Lung Cancer GroupOTHER | 0 | Jun 13, 2022 | clinicaltrials |
| NCT02142738 | Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024) | completed | Phase 3 | 305 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 13, 2022 | clinicaltrials |
Data updated 22 days agoSource updated Jan 17, 2024source: clinicaltrials